Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure: Real-World Assessment of Spleen, Symptoms, and Hematologic Response
暂无分享,去创建一个
C. Harrison | J. Mascarenhas | B. Feinberg | A. Gerds | A. McBride | J. Kish | A. Kee | P. Abraham | D. Liassou | A. Balanean | J. Nadal